Skip to contentO
OptimizeRx Corp
O
OPRXOptimizeRx Corp Q3 2024 · 10-Q
Revenue$21.31M$21.31M+30.5% vs Q3 2023 Net Income-$9.12M-$9.12MN/M vs Q3 2023 EPS Diluted-$0.50-$0.50N/M vs Q3 2023 Gross Profit$13,447,000+37.2% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
OptimizeRx Corp · CIK 1448431 · Engraved from SEC EDGAR
Operating Cash Flowderived$1,791,000+21.6% Free Cash Flowderived$1,773,000+23.2% Margins · derivedGross margin63.1%+3.1 pt vs Q3 2023
Operating margin-40.2%−18.4 pt vs Q3 2023
Net margin-42.8%−25.3 pt vs Q3 2023
ended Sep 30, 2024 · filed Nov 14, 2024 · 45 d after period end